GlassScriptPhysician profile
Dina O'Connor
NPI 1841745908
$3,717.27
in general payments reported to CMS, 2019-2025
25 companies · $1,030 in 2025
The $1,030 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $859 · 2022: $396 · 2023: $417 · 2024: $1,015 · 2025: $1,030.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,363 · Education: $98.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,363.01 |
| Education | $98.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $2,198.58 | 2021-2025 | Enhertu, Datroway |
| Taiho Oncology, INC. | $364.75 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $175.42 | 2021-2025 | Enhertu, Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $118.12 | 2022-2025 | Opdivo |
| Novartis Pharmaceuticals Corporation | $86.46 | 2023-2025 | |
| Genentech USA, INC. | $79.35 | 2024-2025 | Tecentriq, Itovebi |
| Merck Sharp & Dohme LLC | $79.27 | 2022-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $66.73 | 2021-2025 | |
| Deciphera Pharmaceuticals INC. | $61.86 | 2023-2025 | Qinlock, Romvimza |
| Amgen INC. | $58.72 | 2021-2023 | Xgeva, Vectibix |
| Takeda Pharmaceuticals U.S.A., INC. | $58.67 | 2023-2025 | Fruzaqla |
| Foundation Medicine, INC. | $55.64 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $54.11 | 2025 | Sancuso |
| Eisai INC. | $43.81 | 2022-2025 | |
| Seagen INC. | $30.00 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $27.73 | 2024-2025 | Onivyde |
| Digestive Care, INC. | $21.26 | 2023 | Pertzye |
| Biocon Biologics INC | $19.81 | 2024 | Ogivri |
| Janssen Scientific Affairs, LLC | $17.82 | 2024 | Erleada |
| Lilly USA, LLC | $17.56 | 2025 | Jaypirca, Verzenio |
| Beone Medicines USA, INC. | $17.54 | 2025 | Tevimbra |
| Jazz Pharmaceuticals INC. | $17.19 | 2025 | |
| Abbvie INC. | $16.90 | 2024 | |
| Array Biopharma INC | $16.17 | 2025 | Braftovi |
| Servier Pharmaceuticals LLC | $13.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dina O'Connor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.